Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009.
about
Getting to 90-90-90 in paediatric HIV: What is needed?Mitochondrial toxicity studied with the PBMC of children from the Chinese national pediatric highly active antiretroviral therapy cohort.The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infectionViral hepatitis and human immunodeficiency virus co-infections in AsiaPrevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenHIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.HIV/HBV coinfection in children and antiviral therapy.Prevalence of hepatitis B co-infection amongst HIV infected children attending a care and treatment centre in Owerri, South-eastern Nigeria.Prevalence and Clinical and Immunoviralogical Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, NigeriaPrevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children.Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain.Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.Seroprevalence of Hepatitis B Among HIV-infected Children and Adolescents Receiving Antiretroviral Therapy in the TREAT Asia Pediatric HIV Observational Database
P2860
Q30385352-3DC80C44-A23D-4D31-8157-D822B99FA617Q34611901-C66F2BFF-AD03-4790-B4A2-01DC4C0E2050Q35454587-6E745F81-5E06-42B4-94EC-0B157E271E87Q35567832-D79188AB-7BD2-4220-9C55-45D2304B93C3Q35619539-DBFA4CF2-4579-4609-8843-06C0521A8F5FQ36349683-1F7EC0CA-8DEC-4DB6-82DE-A92F51EC7122Q36439101-9548E56E-A147-473F-9B51-1F6F573695C8Q36705583-817CBE09-724F-4A6A-95DD-E4C7329A2F2AQ36775147-BCAC1C12-982C-4090-9CEC-FE2B4BF25724Q36811459-B0C12952-19A0-4162-A3B3-2D699DAAE9FBQ36830085-A561D7E0-6441-4C0B-BFC6-7C443F431C46Q37420263-BA99BFFE-76E9-46BD-A575-EC04043848FBQ40298785-FF63DE1A-1B5E-4E70-8244-C41A03EF7417Q40398857-3EB6EA3D-19FA-4CC0-9240-D12CC0FFCC3BQ57173402-07F6BAD1-A376-40C7-980F-0D9F8D82FF9C
P2860
Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@ast
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@en
type
label
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@ast
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@en
prefLabel
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@ast
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@en
P2093
P2860
P1476
Hepatitis B and hepatitis C se ...... infection in China, 2005-2009.
@en
P2093
Fujie Zhang
Matthew Robinson
Shuntai Zhou
Zhihui Dou
P2860
P304
P356
10.1097/QAI.0B013E3181C99226
P407
P577
2010-06-01T00:00:00Z